|
Optimizing Care of Patients with AMD: From Recognition to Treatment
|
|
Facebook
LinkedIn
E-Mail
|
(1807)
|
Released: 01/30/2024 Expires: 01/31/2025 (subject to change)
- CE for this activity will not be available after this date.
Overview
Nurse Practitioners Dr. Tulay Cakiner-Egilmez and Dr. Audrey Stevenson guide learners through the identification of AMD (age-related macular degeneration) in primary care, referral, and treatment. The interactive case studies activity allows the learner to apply the knowledge from the presentation.
Objectives - Identify the risk factors associated with AMD.
- Recall the signs and symptoms associated with AMD.
- Discuss the referral pathway needed to optimize ophthalmology care for patients at risk for, or with symptoms suggestive of, AMD.
- Develop nonpharmacologic or pharmacologic treatment plans for patients with AMD.
- Incorporate shared decision-making when addressing barriers to treatment with patients with AMD.
Speakers Tulay Cakiner-Egilmez, NP-BC, PhD, CRNO, COMT Audrey Stevenson, PhD, MPH, MSN, FNP-BC
Disclosure This program was planned in accordance with AANP CE Standards and Policies.The speakers have the following disclosures: - Tulay Cakiner-Egilmez
- Audrey Stevenson
- Sanofi Pasteur-Speaker Bureau and Advisory Board
- GSK-Speaker Bureau and Advisory Board
- Pfizer-Advisory Board
- Merck-Speaker Bureau and Advisory Board
All Planners involved in this activity have no relevant financial relationships to disclose. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Disclaimer Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions- Read this activity description, including objectives and disclosures.
- Complete the educational content:
- Access the first part of the activity labeled "Video Activity."
- Complete the pre-test.
- Click the Play button to watch the activity presentation. Full participation credit for the activity will be received once the entire video has been watched.
- Complete the post-test.
- Access the second part of the activity labeled "Case Studies"
- Click the Play button to launch the interactive activity. Full participation credit for the activity will be received once the end of the activity has been reached.
- Access additional downloadable content by clicking on the Additional Resources button (handouts, post-test reviews, any other downloadable resources).
- After completing both the video and case study content, return to the parent-module and click on the blue Next Steps button:
- Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1.25 Contact Hour(s) of CE, 0.5 of which may be applied towards Pharmacology
|
|
|
|